{"organizations": [], "uuid": "b3d3bb266b1f99639782293245cf796672d87afc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180514.html", "section_title": "Archive News &amp; Video for Monday, 14 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-unum-therapeutics-posts-q1-loss-of/brief-unum-therapeutics-posts-q1-loss-of-0-66-per-share-idUSASC0A1W2", "country": "US", "domain_rank": 408, "title": "BRIEF-Unum Therapeutics Posts Q1 Loss Of $0.66 Per Share", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-14T19:17:00.000+03:00", "replies_count": 0, "uuid": "b3d3bb266b1f99639782293245cf796672d87afc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-unum-therapeutics-posts-q1-loss-of/brief-unum-therapeutics-posts-q1-loss-of-0-66-per-share-idUSASC0A1W2", "ord_in_thread": 0, "title": "BRIEF-Unum Therapeutics Posts Q1 Loss Of $0.66 Per Share", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "unum", "sentiment": "negative"}, {"name": "unum therapeutics inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "unum therapeutics", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 14 (Reuters) - Unum Therapeutics Inc:\n* UNUM THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE\n* Q1 LOSS PER SHARE $0.66 * Q1 EARNINGS PER SHARE VIEW $-0.36 â€” THOMSON REUTERS I/B/E/S\n* UNUM THERAPEUTICS - ON TRACK TO FILE IND FOR FIRST SOLID TUMOR PROGRAM, ACTR707 IN COMBINATION WITH TRASTUZUMAB IN 2H 2018\n* AS OF MARCH 31, 2018, UNUM HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $32.4 MILLION\n* UNUM - PROCEEDS FROM IPO,CONCURRENT PLACEMENT,EXISTING CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES, WILL FUND EXPENSES THROUGH AT LEAST DEC 2019 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-14T19:17:00.000+03:00", "crawled": "2018-05-15T14:00:50.004+03:00", "highlightTitle": ""}